Decentralized Medicine (DeMed): A Paradigm Shift in Cancer Therapy (2025)

Abstract

Decentralized Medicine (DeMed) represents a transformative approach to cancer therapy, shifting from traditional centralized hospital-based care and clinical trial models to patient-centric, digitally enabled, and distributed care delivery systems. This paradigm leverages blockchain, artificial intelligence (AI), and digital health technologies to distribute healthcare resources, data, and decision-making, emerges as a transformative strategy. By enabling patient-controlled data sharing, decentralized clinical trials (DCTs), and AI-driven personalized treatments, DeMed accelerates evidence generation, enhances equity, and reduces barriers in cancer care. This review explores the epidemiology of cancer, updated hallmarks, molecular mechanisms targeted through DeMed, integration with emerging technologies like zero-knowledge proofs, challenges in implementation, and the potential for more effective, inclusive therapies, including metabolic interventions such as repurposed drugs and dietary strategies.

Introduction

Cancer care has historically been delivered through centralized healthcare facilities where diagnosis, treatment, monitoring, and clinical trials occur under one roof. However, this model creates geographical barriers, limits trial participation diversity, and imposes logistical and cost burdens on patients, particularly those in rural or underserved regions. 

Decentralized Medicine re-envisions cancer therapy as an ecosystem distributed across multiple points of care, including patient homes, community clinics, and local laboratories. The integration of digital tools allows real-time data collection, remote symptom management, and home administration of therapies, significantly increasing patient convenience and inclusivity.

Decentralized Manufacturing: Expanding Access to Advanced Therapies

Advanced cancer therapies, such as Chimeric Antigen Receptor T-cell (CAR-T) treatments, require complex manufacturing processes traditionally centralized in specialized urban facilities. This centralized manufacturing model (CMM) limits therapy availability due to logistical constraints like transportation, scaling, and infrastructure needs. Moving towards a Decentralized Manufacturing Model (DMM), or "scale-out" approach, onsite or near-patient manufacturing facilities can be established to produce personalized therapies closer to the point-of-care. This approach reduces delays, lowers costs, and expands access to CAR-T and other cell and gene therapies across diverse populations and geographic locations, particularly benefiting rural and suburban regions. (realm)

Decentralized Clinical Trials: Patient-Centric Research Models

Decentralized Clinical Trials (DCTs) disrupt the conventional clinical research paradigm by bringing trial activities to patients rather than requiring patients to visit centralized research sites. Utilizing telemedicine, local healthcare providers, mobile health apps, and home health services, DCTs enable remote consent, virtual visits, home delivery of investigational drugs, and local lab or imaging procedures. DCTs have been accelerated by regulatory flexibilities introduced during the COVID-19 pandemic and demonstrate potential in increasing participant diversity, improving retention, and alleviating social and logistical barriers traditionally affecting trial enrollment. Importantly, DCTs provide equitable opportunities for historically underrepresented groups, such as rural populations and racial minorities, to engage in clinical research. (fda)

Digital Health and AI Integration

The backbone of DeMed relies on digital health technologies—wearable devices, electronic patient-reported outcomes platforms, telehealth consultations, and AI-driven analytics. Real-time data collection and remote monitoring facilitate early detection of adverse events, personalized treatment adjustments, and enhanced adherence to therapy. Furthermore, AI and blockchain offer opportunities to streamline decentralized trial management, secure patient data, and optimize patient recruitment and outcome prediction. These technologies underpin the scalability and sustainability of decentralized cancer care models. (pubmed.ncbi.nlm.nih)

Benefits of Decentralized Cancer Therapy

• Improved Access: Removes geographic and logistical barriers by enabling therapy and trial participation closer to home.

• Increased Diversity: Enhances representation of diverse patient populations in clinical trials, addressing disparities.

• Patient-Centered Care: Tailors treatment delivery to patient preferences, decreasing hospital visits and improving quality of life.

• Faster Innovation: Expedites data collection and decision-making processes in clinical trials through digital tools.

• Cost Reduction: Lowers travel and accommodation expenses for patients and operational costs for sponsors.

Challenges and Considerations

• Regulatory Compliance: Aligning decentralized methods with existing regulatory frameworks requires ongoing dialogue with authorities.

• Data Privacy and Security: Ensuring compliance with data protection laws and maintaining patient confidentiality is paramount.

• Technological Disparities: Digital literacy and access to technology must be addressed to avoid excluding vulnerable populations.

• Clinical Safety: Careful monitoring and clear protocols are essential for safe administration of treatments remotely, especially parenteral therapies.

• Infrastructure and Training: Local healthcare providers need training and resources to support decentralized models effectively.

Conclusion

Decentralized Medicine signifies a pivotal change in cancer therapy, enabling a more equitable, patient-friendly, and technologically empowered healthcare ecosystem. Through decentralized manufacturing of advanced therapies and the proliferation of decentralized clinical trials supported by digital innovation, DeMed addresses critical barriers in oncology care access and research. With careful implementation and regulatory collaboration, DeMed holds the potential to redefine cancer treatment paradigms and improve outcomes for patients worldwide.

---

References:

1. https://www.realm.bio/wp-content/uploads/2024/04/Whitepaper-4-Beyond-Urban-Centers-Expanding-CAR-T-Therapy-with-Decentralized-Manufacturing1.pdf
2. https://www.fda.gov/about-fda/oncology-center-excellence/advancing-oncology-decentralized-trials
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC11622315/
4. https://caringcross.org/wp-content/uploads/2021/11/Part-1-Overview-and-Logistics-1.pdf
5. https://download.uol.com.br/files/2025/07/2438081543_roche-decentralized-care_final-281-29.pdf
6. https://www.iqvia.com/library/white-papers/decentralized-oncology-trials-how-digital-health-and-covid-19-are-transforming-cancer-research
7. https://www.acrohealth.org/wp-content/uploads/2023/11/ACRO-DCT-White-Paper-2020-DCT_vs06.pdf
8. https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/seizing-opportunities.pdf
9. https://ecpc.org/wp-content/uploads/2019/08/ecpc-white-paper-the-value-of-innovation-in-oncology-2.pdf
10. https://ascopubs.org/doi/10.1200/JCO.22.00358
11. https://ascopubs.org/doi/10.1200/OP.22.00702
12. https://pubmed.ncbi.nlm.nih.gov/40779078/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11277430/
14. https://journal.waocp.org/article_91616_f1276c1fa0bfba5af56a944b1b2c093a.pdf